Substance P
Also known as: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2, Neurokinin A, Neurokinin SP, SP, Substance P, Substance P free acid, TAC1 peptide product
Source Substance P at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Substance P is a tachykinin neuropeptide found in sensory nerves and various tissues, including fascia. It is frequently measured as a biomarker of pain, inflammation, and nausea in clinical research. Studies have examined how interventions such as acupuncture, dry needling, and peri‑operative drugs influence its circulating levels.
Mechanism of Action
Substance P is released from sensory nerve endings and can be detected in blood or tissue samples. In the cited research it serves as a marker of neurogenic inflammation and nociceptive activity, with changes in its concentration accompanying alterations in pain‑related outcomes.
What the Research Shows
Clinical investigations have measured substance P in several contexts. A randomized trial of pyridoxine for postoperative nausea and vomiting reported no significant difference in plasma substance P between treatment and control groups, despite reduced nausea incidence. Systematic reviews of acupuncture for endometriosis‑related pain and of dry needling report that these techniques lower substance P levels alongside pain relief. A review of fascial innervation identified substance P as one of the most commonly detected neuropeptides in fascia, suggesting its involvement in musculoskeletal pain. Overall, evidence links reductions in substance P with improved pain outcomes, but direct therapeutic manipulation of the peptide remains unstudied.
Reported Benefits
Evidence from acupuncture and dry needling studies indicates that lowering substance P concentrations may be associated with reduced pain severity in conditions such as endometriosis and musculoskeletal disorders. These findings suggest a potential benefit of interventions that modulate substance P, although the peptide itself has not been administered as a treatment.
Limitations of the Evidence
No clinical trials have evaluated substance P as a therapeutic agent; all data are observational or pertain to its role as a biomarker. The cited studies vary in design, sample size, and quality, and the relationship between substance P changes and clinical outcomes remains correlational. Further randomized, controlled research is needed to clarify causality.
Safety Considerations
The abstracts provide no information on adverse events related to exogenous substance P administration. As an endogenous peptide involved in inflammatory signaling, theoretical concerns include promoting vasodilation and plasma extravasation, but no safety data are available from the cited literature. Caution is warranted when interpreting its modulation in clinical settings.
How It Is Administered
Research use of substance P has involved routes such as intra‑articular, intradermal, intrathecal, and intravenous administration, typically in controlled experimental settings. Formulations are generally peptide solutions prepared for precise dosing under laboratory conditions.
Routes of Administration
Goals & Uses
- Pain research / nociception modulationResearchHigh
- Depression / anxiety researchResearchModerate
- anti‑inflammatory modulationInflammationLow
- Wound healingDermatologicModerateTissue repair and wound healing
- Wound healing (investigational)Investigational TherapeuticLow
- Emesis / nausea researchResearchHigh
- AnalgesiaPain ManagementModerate
- Neurogenic inflammation characterizationResearchHigh
Contraindications
- Chronic pain conditions requiring stable managementPainModerate
- Severe hypotension or cardiovascular instabilityCardiovascularHigh
- Hypersensitivity to Substance P or tachykininsAllergyHigh
Adverse Effects
- HypotensionCardiovascularCommonLow blood pressure
- Nausea/vomitingGastrointestinalUncommon
- FlushingVascularCommonWarmth and redness of the skin
- Increased vascular permeability / edemaInflammatoryCommon
- Pain or burning at injection siteLocalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- BronchoconstrictionRespiratoryUncommon
Drug Interactions
- Aprepitant / FosaprepitantHigh
- ACE inhibitors (e.g., captopril, enalapril)Moderate
- Neutral endopeptidase inhibitors (neprilysin inhibitors)Moderate
- Opioids (e.g., morphine)Low
Population Constraints
- Asthma / reactive airway diseasePulmonaryRelative
- PregnancyReproductive SafetyRelative
- Pediatric populationsAgeRelative
- Patients with inflammatory bowel diseaseGastrointestinalRelative
Regulatory Status
- European UnionUnapprovedNot authorized for clinical use
- United StatesUnapprovedInvestigational peptide only
- United KingdomUnapprovedResearch use only
Not approved by FDA, EMA, or MHRA as a therapeutic drug. Used extensively in preclinical and clinical research. NK1 receptor antagonists targeting the Substance P pathway are approved for chemotherapy-induced nausea and vomiting.
Evidence & Sources
- Journal ArticleModerateZhang Q, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleHighChen C, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighRabanal-Rodríguez G, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleHighSuarez-Rodriguez V, et al.2022-01-01T00:00:00.000000Z
Frequently Asked Questions
What is substance P?
Substance P is a small protein (neuropeptide) released by sensory nerves. It is commonly measured in blood or tissue as an indicator of pain and inflammation in research studies.
Does giving substance P relieve pain?
Current research does not evaluate substance P as a treatment. Studies have only measured its levels, and reductions in substance P after interventions like acupuncture have been linked to pain relief, but the peptide itself has not been shown to be therapeutic.
Can substance P levels predict nausea after surgery?
In a trial of pyridoxine for postoperative nausea, substance P levels did not differ between patients who did or did not develop nausea, suggesting it was not a reliable predictor in that setting.
Is it safe to use substance P in humans?
The cited literature provides no safety data for administering substance P. Because it participates in inflammatory pathways, potential risks are uncertain, and any use remains limited to experimental research.
How is substance P measured in studies?
Researchers typically collect blood samples and quantify substance P using enzyme‑linked immunosorbent assay (ELISA) kits, as reported in the postoperative nausea trial and other biomarker studies.
What is Substance P used for?
Substance P is educationally associated with: Pain research / nociception modulation, Depression / anxiety research, anti‑inflammatory modulation, Wound healing, Wound healing (investigational), Emesis / nausea research, Analgesia, Neurogenic inflammation characterization. Educational only — not medical advice.
How is Substance P administered?
Recorded routes of administration: Intraarticular, Intradermal, Intranasal, Intrathecal, Intravenous, Topical.
What are the potential side effects of Substance P?
Reported adverse effects include: Hypotension, Nausea/vomiting, Flushing, Increased vascular permeability / edema, Pain or burning at injection site, Nausea, Bronchoconstriction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Substance P?
Recorded contraindications: Chronic pain conditions requiring stable management, Severe hypotension or cardiovascular instability, Hypersensitivity to Substance P or tachykinins. Consult a qualified clinician before use.